Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


11.09.2017

1 Adv Healthc Mater
1 Anticancer Res
1 Biochem Biophys Res Commun
1 BJU Int
1 BMC Cancer
1 BMC Urol
1 Cancer Discov
1 Cancer Med
1 Cell Physiol Biochem
1 Clin Cancer Res
1 Clin Genitourin Cancer
1 Curr Urol
1 DNA Cell Biol
1 Eur J Epidemiol
1 Eur Urol Focus
1 Food Chem Toxicol
1 Hernia
1 Int J Cancer
1 Int J Pharm
1 J Urol
2 Med Oncol
1 Mol Carcinog
2 Oncotarget
1 PLoS One
1 Rambam Maimonides Med J
1 Toxicol Appl Pharmacol
1 Urologia
1 Zhonghua Bing Li Xue Za Zhi


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Adv Healthc Mater

  1. ACHARYA AP, Theisen KM, Correa A, Meyyappan T, et al
    An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation.
    Adv Healthc Mater. 2017 Sep 8. doi: 10.1002/adhm.201700808.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. CIMPEAN AM, Tarlui V, Cumpanas AA, Bolintineanu S, et al
    Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
    Anticancer Res. 2017;37:4935-4942.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  3. WANG D, Kong X, Li Y, Qian W, et al
    Curcumin inhibits bladder cancer stem cells by suppressing Sonic Hedgehog pathway.
    Biochem Biophys Res Commun. 2017 Sep 4. pii: S0006-291X(17)31732.
    PubMed     Text format     Abstract available


    BJU Int

  4. LI R, Metcalfe MJ, Ferguson Rd JE, Mokkapati S, et al
    Effects of Thiazolidinedione in Patients with Active Bladder Cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14009.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. NEUZILLET Y, Chapeaublanc E, Krucker C, De Koning L, et al
    IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
    BMC Cancer. 2017;17:636.
    PubMed     Text format     Abstract available


    BMC Urol

  6. SCHROECK FR, Sirovich B, Seigne JD, Robertson DJ, et al
    Assembling and validating data from multiple sources to study care for Veterans with bladder cancer.
    BMC Urol. 2017;17:78.
    PubMed     Text format     Abstract available


    Cancer Discov


  7. Local Delivery of IFNalpha Has Antitumor Activity in Bladder Cancer.
    Cancer Discov. 2017 Sep 1. doi: 10.1158/2159-8290.CD-RW2017.
    PubMed     Text format     Abstract available


    Cancer Med

  8. ECKE TH, Stier K, Weickmann S, Zhao Z, et al
    miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
    Cancer Med. 2017 Sep 6. doi: 10.1002/cam4.1161.
    PubMed     Text format     Abstract available


    Cell Physiol Biochem

  9. XIONG Y, Wang L, Li Y, Chen M, et al
    The Long Non-Coding RNA XIST Interacted with MiR-124 to Modulate Bladder Cancer Growth, Invasion and Migration by Targeting Androgen Receptor (AR).
    Cell Physiol Biochem. 2017;43:405-418.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. WU S, Zheng J, Li Y, Yu H, et al
    A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1510.2017.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  11. BAGRODIA A, Sukhu R, Winer AG, Levy E, et al
    Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30232.
    PubMed     Text format     Abstract available


    Curr Urol

  12. BROWNE C, Davis NF, Nolan WJ, MacCraith ED, et al
    Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy.
    Curr Urol. 2017;10:132-135.
    PubMed     Text format     Abstract available


    DNA Cell Biol

  13. YE JR, Liu L, Zheng F
    Long Noncoding RNA Bladder Cancer Associated Transcript 1 Promotes the Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer Through Sponging miR-144.
    DNA Cell Biol. 2017 Sep 8. doi: 10.1089/dna.2017.3854.
    PubMed     Text format     Abstract available


    Eur J Epidemiol

  14. VRIELING A
    Lifestyle and bladder cancer prevention: no consistent evidence from cohort studies.
    Eur J Epidemiol. 2017 Sep 4. doi: 10.1007/s10654-017-0306.
    PubMed     Text format    


    Eur Urol Focus

  15. HADEN TD, Prunty MC, Jones AB, Deroche CB, et al
    Comparative Perioperative Outcomes in Septuagenarians and Octogenarians Undergoing Radical Cystectomy for Bladder Cancer-Do Outcomes Differ?
    Eur Urol Focus. 2017 Aug 30. pii: S2405-4569(17)30197.
    PubMed     Text format     Abstract available


    Food Chem Toxicol

  16. MORENO-LONDONO AP, Bello-Alvarez C, Pedraza-Chaverri J
    Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line.
    Food Chem Toxicol. 2017 Sep 1. pii: S0278-6915(17)30506.
    PubMed     Text format     Abstract available


    Hernia

  17. NARANG SK, Alam NN, Campain NJ, Pathak S, et al
    Parastomal hernia following cystectomy and ileal conduit urinary diversion: a systematic review.
    Hernia. 2017;21:163-175.
    PubMed     Text format     Abstract available


    Int J Cancer

  18. MASAOKA H, Matsuo K, Sawada N, Yamaji T, et al
    Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2017 Sep 5. doi: 10.1002/ijc.31028.
    PubMed     Text format     Abstract available


    Int J Pharm

  19. KOLAWOLE OM, Lau WM, Mostafid H, Khutoryanskiy VV, et al
    Advances in intravesical drug delivery systems to treat bladder cancer.
    Int J Pharm. 2017 Aug 31. pii: S0378-5173(17)30834.
    PubMed     Text format     Abstract available


    J Urol

  20. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Med Oncol

  21. KATZ H, Wassie E, Alsharedi M
    Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Med Oncol. 2017;34:170.
    PubMed     Text format     Abstract available

  22. LIEM EIML, Baard J, Cauberg ECC, Bus MTJ, et al
    Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
    Med Oncol. 2017;34:172.
    PubMed     Text format     Abstract available


    Mol Carcinog

  23. OWEIDA A, Bhatia S, Hirsch K, Calame D, et al
    Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.
    Mol Carcinog. 2017;56:1189-1196.
    PubMed     Text format     Abstract available


    Oncotarget

  24. WU J, Yu C, Cai L, Lu Y, et al
    Effects of increased Kindlin-2 expression in bladder cancer stromal fibroblasts.
    Oncotarget. 2017;8:50692-50703.
    PubMed     Text format     Abstract available

  25. WHANG YM, Jin SB, Park SI, Chang IH, et al
    MEK inhibition enhances efficacy of bacillus Calmette-Guerin on bladder cancer cells by reducing release of Toll-like receptor 2-activated antimicrobial peptides.
    Oncotarget. 2017;8:53168-53179.
    PubMed     Text format     Abstract available


    PLoS One

  26. DROOP J, Szarvas T, Schulz WA, Niedworok C, et al
    Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.
    PLoS One. 2017;12:e0176287.
    PubMed     Text format     Abstract available


    Rambam Maimonides Med J

  27. CLINTON T, Lotan Y
    Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.
    Rambam Maimonides Med J. 2017 Aug 22. doi: 10.5041/RMMJ.10314.
    PubMed     Text format     Abstract available


    Toxicol Appl Pharmacol

  28. SLUSSER-NORE A, Garrett SH, Zhou XD, Sens DA, et al
    The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.
    Toxicol Appl Pharmacol. 2017;331:41-53.
    PubMed     Text format     Abstract available


    Urologia

  29. KATAFIGIOTIS I, Sfoungaristos S, Martini A, Stravodimos K, et al
    Bladder cancer to patients younger than 30 years: a retrospective study and review of the literature.
    Urologia. 2017 Sep 5:0. doi: 10.5301/uj.5000264.
    PubMed     Text format     Abstract available


    Zhonghua Bing Li Xue Za Zhi

  30. HUANG RF, He C, Zhu WF, Li Y, et al
    [Application of immunohistochemistry for p16 and GATA3 and molecular HPV typing in diagnosis of secondary bladder involvement by cervical carcinoma].
    Zhonghua Bing Li Xue Za Zhi. 2017;46:388-392.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: